1. Home
  2. FMST vs VTGN Comparison

FMST vs VTGN Comparison

Compare FMST & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foremost Lithium Resource & Technology Ltd.

FMST

Foremost Lithium Resource & Technology Ltd.

N/A

Current Price

$1.17

Market Cap

22.3M

ML Signal

N/A

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.26

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMST
VTGN
Founded
2005
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3M
10.8M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
FMST
VTGN
Price
$1.17
$0.26
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
94.0K
2.9M
Earning Date
05-21-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.09
$0.20
52 Week High
$4.57
$5.14

Technical Indicators

Market Signals
Indicator
FMST
VTGN
Relative Strength Index (RSI) 39.44 39.16
Support Level $1.09 $0.22
Resistance Level $1.94 $0.32
Average True Range (ATR) 0.08 0.02
MACD -0.00 0.00
Stochastic Oscillator 23.08 11.82

Price Performance

Historical Comparison
FMST
VTGN

About FMST Foremost Lithium Resource & Technology Ltd.

Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: